The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 22, 2026
Filed:
Dec. 18, 2020
Applicant:
Sri International, Menlo Park, CA (US);
Inventors:
Ling Jong, Menlo Park, CA (US);
Nathan Collins, Menlo Park, CA (US);
Raymond Ng, Menlo Park, CA (US);
Assignee:
SRI International, Menlo Park, CA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07C 217/86 (2006.01); C07C 211/53 (2006.01); C07C 211/54 (2006.01); C07C 211/56 (2006.01); C07C 217/92 (2006.01); C07D 209/14 (2006.01); C07D 213/74 (2006.01); C07D 215/38 (2006.01); C07D 249/08 (2006.01); C07D 295/13 (2006.01); C07D 305/08 (2006.01); C07D 309/04 (2006.01); C07D 401/12 (2006.01); C07D 403/06 (2006.01); C07D 403/12 (2006.01); C07D 405/06 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 409/12 (2006.01); C07D 413/12 (2006.01);
U.S. Cl.
CPC ...
C07C 217/86 (2013.01); C07C 211/53 (2013.01); C07C 211/54 (2013.01); C07C 211/56 (2013.01); C07C 217/92 (2013.01); C07D 209/14 (2013.01); C07D 213/74 (2013.01); C07D 215/38 (2013.01); C07D 249/08 (2013.01); C07D 295/13 (2013.01); C07D 305/08 (2013.01); C07D 309/04 (2013.01); C07D 401/12 (2013.01); C07D 403/06 (2013.01); C07D 403/12 (2013.01); C07D 405/06 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 413/12 (2013.01);
Abstract
Various embodiments of the present disclosure are directed to compounds having Formula I, Formula II, Formula IIA, Formula III, Formula IIIA, Formula IIIB, and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases and/or treating associated diseases. In some embodiments, subject compounds are used to prepare a composition that is effective in treating neurodegenerative diseases.